News & Events about Rhythm Pharmaceuticals Inc.
- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet Journal of Rare Diseases - BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (...
Canaccord Genuity Group reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM Get Rating) in a report issued on Wednesday, Benzinga reports. A number of other equities analysts have also weighed in on RYTM. The Goldman Sachs Group upped their target price on shares of ...
Globe Newswire
2 months ago
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway ...
Globe Newswire
2 months ago
-- Health Canada accepts for review new drug submission for setmelanotide for the treatment of obesity and control of hunger in BBS and biallelic POMC, PCSK1 and LEPR deficiencies -- BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage ...
Globe Newswire
4 months ago
Understanding Hunger & Bardet-Biedl Syndrome (BBS): Gabes Story
Developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation
-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International -- BOSTON, Sept...